With $160 million in new funding, Freenome looks to commercialize its blood test to detect colorectal cancer

With $160 million in new funding, Freenome looks to commercialize its blood test to detect colorectal cancer

And it’s why they’re investing more than $160 million in the South San Francisco-based startup, Freenome. “If I could do it with less money and do it responsibly, I would,” says Gabriel …